Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-KPd Quadruple Therapy for High-Risk Newly Diagnosed Multiple Myeloma
ChiCTR2500104311Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of daratumumab, carfilzomib, pomalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Overall response rate and Minimal residual disease negativity rate after consolidation. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
daratumumabcarfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500104311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104311.